BioCardia Appoints Marvin Slosman To Its Board, Thanking Dr. Richard Krasno For Nearly A Decade Of Service

BioCardia, Inc., a global leader in cellular and cell-derived therapies for cardiovascular and pulmonary diseases, announced that Mr. Marvin Slosman has been elected to its Board of Directors, effective December 2, 2025. The company also shared that Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and stepped down on the same date.

Peter Altman, Chief Executive Officer of BioCardia, said the company is pleased to welcome Mr. Slosman to its Board. He noted that Mr. Slosman brings extensive experience in the interventional cardiology sector and has successfully led breakthrough medical technologies from early development through commercialization. Altman added that Mr. Slosman’s deep understanding of regulatory pathways, global market expansion, and clinical value generation will support BioCardia as it continues to grow its product portfolio and deliver innovative therapies to patients.

Mr. Slosman currently serves as President, Chief Executive Officer, and Director of InspireMD, a NASDAQ-listed medical device company focused on vascular and carotid-artery disease solutions. Throughout his career, he has held senior leadership positions including CEO and Chief Operating Officer roles, as well as commercial leadership positions at major healthcare companies such as Johnson & Johnson, GE Healthcare, and Baxter International. His background includes significant achievements in bringing products to market, forming strategic partnerships, navigating regulatory approvals, and advancing technology platforms across global medical device markets.

BioCardia also expressed its appreciation for Dr. Richard Krasno’s service and contributions during his nine-year tenure. CEO Altman acknowledged Dr. Krasno’s important role in guiding the company through several major milestones, including the development of clinical evidence for the CardiAMP cell therapy program for ischemic heart failure, FDA approval of the Morph DNA product, and expansion into therapeutic areas such as chronic myocardial ischemia, acute myocardial infarction, and pulmonary disease.

Dr. Krasno served on multiple Board committees, including the Audit and Compensation Committees, where he played a key role in strengthening the company’s governance and supporting long-term strategic planning. The Board and executive leadership team welcomed Mr. Slosman’s expertise and expressed sincere gratitude to Dr. Krasno for his dedication and lasting impact on BioCardia’s mission to advance innovative therapies for cardiovascular disease.